Table 1.
Baseline of the demographic and related clinical characteristics for patients diagnosed with chondrosarcoma.
| Characteristics | With PM | Without PM | Entire cohort | χ2 | P | |||
|---|---|---|---|---|---|---|---|---|
| n=69 | 6.8% | n=945 | 93.2% | N=1014 | % | |||
| Sex | χ2=1.086 | 0.297 | ||||||
| Female | 26 | 5.9% | 417 | 94.1% | 443 | 43.7% | ||
| Male | 43 | 7.5% | 528 | 92.5% | 571 | 56.3% | ||
| Age (52.68±17.64) range (4–95) | χ2=2.101 | 0.147 | ||||||
| ≤67 | 50 | 6.2% | 754 | 93.8% | 804 | 79.3% | ||
| >67 | 19 | 9.0% | 191 | 91.0% | 210 | 20.7% | ||
| Race | χ2=1.234 | 0.745 | ||||||
| White | 60 | 6.9% | 812 | 93.1% | 872 | 86.0% | ||
| Black | 6 | 7.9% | 70 | 92.1% | 76 | 7.5% | ||
| Other | 2 | 3.6% | 54 | 96.4% | 56 | 5.5% | ||
| Unknown | 1 | 10.0% | 9 | 90.0% | 10 | 1.0% | ||
| Insurance status | χ2=5.258 | 0.072 | ||||||
| Uninsured | 5 | 15.2% | 28 | 84.8% | 33 | 3.3% | ||
| Insured | 64 | 6.7% | 895 | 93.3% | 959 | 94.6% | ||
| Unknown | 0 | 0.0% | 22 | 100.0% | 22 | 2.2% | ||
| Marital status | χ2=9.640 | 0.008 | ||||||
| Unmarried | 19 | 4.7% | 385 | 95.3% | 404 | 39.8% | ||
| Married | 49 | 9.0% | 497 | 91.0% | 546 | 53.8% | ||
| Unknown | 1 | 1.6% | 63 | 98.4% | 64 | 6.3% | ||
| Primary site | χ2=1.739 | 0.628 | ||||||
| Extremities | 37 | 6.7% | 512 | 93.3% | 549 | 54.1% | ||
| Spine | 4 | 7.0% | 53 | 93.0% | 57 | 5.6% | ||
| Thoracic cage | 11 | 5.3% | 198 | 94.7% | 209 | 20.6% | ||
| Others | 17 | 8.5% | 182 | 91.5% | 199 | 19.6% | ||
| Histologic subtype | χ2=49.181 | <0.001 | ||||||
| Conventional | 39 | 4.7% | 791 | 95.3% | 830 | 81.9% | ||
| Myxoid | 3 | 6.8% | 41 | 93.2% | 44 | 4.3% | ||
| Mesenchymal | 1 | 9.1% | 10 | 90.9% | 11 | 1.1% | ||
| Clear cell | 1 | 5.6% | 17 | 94.4% | 18 | 1.8% | ||
| Dedifferentiated | 25 | 22.5% | 86 | 77.5% | 111 | 10.9% | ||
| Grade | χ2=51.947 | <0.001 | ||||||
| Low grade | 21 | 3.1% | 666 | 96.9% | 687 | 67.8% | ||
| High grade | 36 | 16.9% | 177 | 83.1% | 213 | 21.0% | ||
| Unknown | 12 | 10.5% | 102 | 89.5% | 114 | 11.2% | ||
| Enneking staging | χ2=20.941 | <0.001 | ||||||
| A | 7 | 2.6% | 260 | 97.4% | 267 | 26.3% | ||
| B | 38 | 11.8% | 284 | 88.2% | 322 | 31.8% | ||
| Unknown | 24 | 5.6% | 401 | 94.4% | 425 | 41.9% | ||
| Regional lymph nodes mets | χ2=44.828 | <0.001 | ||||||
| No | 57 | 5.8% | 919 | 94.2% | 976 | 96.3% | ||
| Yes | 6 | 46.2% | 7 | 53.8% | 13 | 1.3% | ||
| Unknown | 6 | 24.0% | 19 | 76.0% | 25 | 2.5% | ||
| Local recurrence | χ2=87.909 | <0.001 | ||||||
| No | 59 | 5.9% | 940 | 94.1% | 999 | 98.5% | ||
| Yes | 9 | 64.3% | 5 | 35.7% | 14 | 1.4% | ||
| Unknown | 1 | 100.0% | 0 | 0.0% | 1 | 0.1% | ||
| Tumor size | χ2=32.863 | <0.001 | ||||||
| ≤8.6 cm | 18 | 3.2% | 550 | 96.8% | 568 | 56.0% | ||
| >8.6–15 cm | 26 | 10.9% | 212 | 89.1% | 238 | 23.5% | ||
| >15 cm | 16 | 15.1% | 90 | 84.9% | 106 | 10.5% | ||
| Unknown | 4 | 3.9% | 98 | 96.1% | 102 | 10.1% | ||
| Primary tumor surgery | χ2=98.059 | <0.001 | ||||||
| No | 34 | 27.4% | 90 | 72.6% | 124 | 12.2% | ||
| Destruction | 0 | 0.0% | 6 | 100.0% | 6 | 0.6% | ||
| Resection | 26 | 3.4% | 731 | 96.6% | 757 | 74.7% | ||
| Amputation | 9 | 7.8% | 107 | 92.2% | 116 | 11.4% | ||
| Surgery, NOS | 0 | 0.0% | 11 | 100.0% | 11 | 1.1% | ||
| Regional lymph nodes removed | χ2=2.579 | 0.108 | ||||||
| No | 68 | 7.1% | 887 | 92.9% | 955 | 94.2% | ||
| Yes | 1 | 1.7% | 58 | 98.3% | 59 | 5.8% | ||
| Chemotherapy | χ2=119.422 | <0.001 | ||||||
| None/unknown | 37 | 4.0% | 882 | 96.0% | 919 | 90.6% | ||
| Yes | 32 | 33.7% | 63 | 66.3% | 95 | 9.4% | ||
| Radiation | χ2=24.117 | <0.001 | ||||||
| None/unknown | 48 | 5.4% | 845 | 94.6% | 893 | 88.1% | ||
| Yes | 21 | 17.4% | 100 | 82.6% | 121 | 11.9% | ||
| Radiation sequence with surgery | χ2=1.772 | 0.412 | ||||||
| None | 61 | 6.5% | 871 | 93.5% | 932 | 91.9% | ||
| Prior | 2 | 14.3% | 12 | 85.7% | 14 | 1.4% | ||
| After | 6 | 8.8% | 62 | 91.2% | 68 | 6.7% | ||
mets – metastasis.